Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Phase 2 Recruiting 24 enrolled Vertex Pharmaceuticals Incorporated

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.

Timeline

Start: 2025-11-19
Primary completion: 2027-07-22
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-407	Unknown	—	Oral

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Summary

Timeline

Drugs

Indications